NCT06705465 Cross-sectorial Rehabilitation of Patients with Lung Cancer
| NCT ID | NCT06705465 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Camilla Balle |
| Condition | Lung Cancer Non-Small Cell Cancer (NSCLC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 130 participants |
| Start Date | 2024-10-07 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 130 participants in total. It began in 2024-10-07 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Four thousand seven hundred patients are diagnosed with lung cancer in Denmark every year. Even though cigarette smoking has declined for decades a decline in lung cancer incidence is still at least a decade away. Only 16% of these patients with lung cancer started in a municipal rehabilitation program. Aim: To investigate if the intervention "early contact conference" can facilitate acceptance of and participation in municipal rehabilitation in patients with lung cancer. Further, to investigate whether the rehabilitation improve the patients' physical ability and quality of life. Thirteen municipalities from Region Hovedstaden have agreed to participate in this cluster randomized controlled trial. The intervention will focus on creating early contact between the Department of Oncology and the municipalities. The conference call will be planned when the patient is at the hospital for the second systemic treatment and a written status will be sent to the GP after the conference video call so that hospital, municipality, and GP will all have the newest knowledge about the patient's general condition The intervention will be easy to implement in clinical practice afterwards if it is a success and the cost of the intervention is low.
Eligibility Criteria
Inclusion Criteria: * patients diagnosed with NSCLC * 1\. line systemic treatment Exclusion Criteria: * cannot speak, understand, and/or read Danish * cognitive/psychologically unfit to give consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06705465 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer Non-Small Cell Cancer (NSCLC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06705465 currently recruiting?
Yes, NCT06705465 is actively recruiting participants. Contact the research team at camilla.sick.balle@regionh.dk for enrollment information.
Where is the NCT06705465 trial being conducted?
This trial is being conducted at Herlev, Denmark.
Who is sponsoring the NCT06705465 clinical trial?
NCT06705465 is sponsored by Camilla Balle. The trial plans to enroll 130 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.